Who we are | CarbonNil Medical

Experience

1994; started working in the Pharmaceutical industry in 1994 as a Pharmaceutical Sales representative for Merck Pharmaceuticals, now Merck Serono.
2006; left Merck Serono in 2006 and founded DGYC ltd, a company specialising in marketing consultancy and interim management in Pharmaceuticals and Medical Devices.
2013; rejoined Merck Serono as Director of Oncology
2015; joined Sobi (Swedish Orphan Biovitrum) as GM for the UK and RoI.
2018; promoted to VP & GM, Northern Europe.
2021; joined GenSight Biologics as VP and Country Manager, UK, Ireland, Nordics and Middle-East to lead the launch of their gene therapy, Lumevoq.
2023; joined the Flynn group (Flynn Pharma, Inresa GMBH, Micropharm) as group CEO on 1st January 2023
2024; joined Rosemont Pharmaceuticals on 1st January 2024 as Interim Commercial Director with responsibility for all commercial activities globally. (excluding USA)
Neil is also a founding director of the charity, Rare Disease Nurse Network, formed to connect nurses and other healthcare professionals within rare disease. The RDNN mission is to build to be able to provide additional nurse support across the UK for those affected by rare disease.
Neil is also a mentor at START Codon in Cambridge, England, giving commercial advice to healthcare start-ups.
Neil holds a BSc (Hons) degree from the University of Liverpool, a diploma from the Chartered Institute of Marketing and a Diploma in Digital Transformation from the University of Cambridge.

Experience

2005; GSK sales representative.
2008; joined Almirall hospital sales representative, later promoted to brand manager in dermatology.
2010; moved to Fresenius Medical Care as Senior Brand Manager
working in chronic kidney disease.
2012; joined DBA as Marketing Manager for DBA working in branded generics before making the move into rare disease.
2014; started at Baxter as a Senior Brand Lead in Haemophilia.
2016; joined SOBI as Business Unit Director, Haemophilia.
2020; promoted to Global Launch Director.
2022; joined GenSight Biologics as UK Operations Manager preparing for the launch of a gene therapy.
2023; promoted to Interim General Manager for the UK
and Ireland before commercial operations were paused due to a European regulatory delay.
2024; consultancy projects for Flynn Pharma and more recently as Head of Commercial for InfectoPharm UK Ltd.
Sarah holds a BA (hons) degree from the University of Derby.

Neil Dugdale